查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2083000

燒傷：市場洞察、流行病學和市場預測（2036 年）

Burns - Market Insight, Epidemiology, and Market Forecast - 2036
出版日期: | 出版商: DelveInsight | 英文 227 Pages | 商品交期: 2-10個工作天內

價格

燒傷洞察與趨勢

  • 目前燒傷治療仍面臨沉重的臨床負擔。這主要是由於嚴重的發炎、免疫和代謝反應可能發展為休克、感染疾病、器官衰竭和長期功能障礙，以及對患者造成顯著的生理和心理影響。
  • 目前的治療主要包括復甦、創傷護理、感染控制、疼痛管理、清創和手術干預，治療方案的選擇取決於燒傷深度和燒傷面積（TBSA）。這些因素仍然是決定治療結果和醫療資源利用的重要因素。
  • 儘管支持性治療取得了進展，但在實現傷口縫合、最佳疤痕形成和組織完全再生方面仍存在局限性，尤其是在深度部分皮層燒傷和全皮層燒傷方面。在這些情況下，手術介入仍然是主要的治療選擇。
  • 已通過核准的先進療法包括 NexoBrid（酶清創術）、StrataGraft（再生皮膚替代物）以及其他細胞療法，如 RECELL 和 Epicel，這反映了向生物學方法和組織保存策略的逐步轉變。
  • 我們的研發管線越來越側重於再生醫學和基於組織工程的解決方案，例如 denovoSkin（CUTISS AG）和 AGLE-102（Aegle Therapeutics），旨在改善皮膚修復，減少對供體部位的依賴，並增強長期功能和美容效果，儘管它們的採用取決於成功的臨床檢驗和監管批准。
  • 總體而言，雖然外科移植仍然是黃金標準，但燒傷治療的格局正在逐漸向基於酶的清創和再生醫學的方法發展，這是由於癒合速度、減少疤痕和功能恢復方面尚未滿足的需求所驅動的。

這份《燒傷治療市場報告》全面分析了當前的市場格局，包括標準治療方案、臨床實踐和不斷發展的治療流程。該報告還評估了燒傷患者負擔、收入和市場佔有率趨勢、患者佔有率尖峰時段以及治療方案的採納情況，並對全球各地區的市場規模和成長率預測（歷史數據和2022-2036年預測）進行了詳細評估。本報告重點關注燒傷治療領域尚未滿足的關鍵醫療需求，分析了競爭格局和臨床狀況，以識別高價值的成長機會，並對未來的市場成長潛力進行了清晰的展望。

燒傷治療市場的主要促進因素

  • 全球燒傷負擔日益加重。

持續高發的燒傷病例，包括工傷、電擊燒傷和火災創傷造成的燒傷，推動了對有效燒傷治療的需求。嚴重燒傷通常需要長期創傷護理、感染控制和重組手術，因此對先進治療方法的需求持續存在。

  • 加速傷口癒合和改善疤痕形成方面存在著巨大的未滿足需求。

傷口縫合、增生性疤痕和功能性併發症仍然是燒傷復健的主要挑戰。因此，旨在促進上皮化、改善組織再生和減少長期疤痕的治療方法正在加速研發。

  • 燒傷創面感染疾病和抗生素抗藥性日益增加

燒傷後皮膚屏障功能受損會增加細菌定植和感染的風險。人們對抗藥性病原體的日益關注，促使人們需要新的抗菌策略和改進的感染控制技術。

  • 再生醫學和生物療法的擴展

幹細胞療法、細胞外囊泡、生長因子和生物工程技術的進步，為促進血管生成、調節發炎和改善燒傷創面再生創造了新的機會。

燒傷的理解和治療流程

燒傷概述及診斷

燒傷是由熱、化學物質、電、輻射或其他因素引起的損傷，導致皮膚和皮下組織受損。燒傷嚴重程度依損傷範圍分類，包括深度（表淺、部分或全層燒傷）和受累體表面積（TBSA）。嚴重燒傷常伴隨組織壞死、發炎、免疫功能障礙、感染風險、創傷治療延遲和疤痕形成。儘管創傷護理、清創、感染控制和重組手術方面取得了進展，但由於增生性疤痕、攣縮和生活品質下降等併發症，仍然存在許多未被滿足的需求，這推動了以改善癒合和組織再生為重點的先進燒傷治療方法的發展。

燒傷的診斷主要基於對損傷深度、總燒傷面積（TBSA）和嚴重程度的評估，這些評估結果指南治療方案的發展。評估包括詳細病歷損傷機制、熱源、發生時間以及相關創傷，隨後進行臨床檢查，以評估傷口特徵、燒傷深度、解剖位置以及併發症，例如吸入性損傷和感染疾病。在嚴重病例中，可能需要進行額外的檢查以評估全身擴散。準確的燒傷評估不僅對指導復甦、清創、傷口處理、感染控制和重組指南至關重要，而且對減輕延遲癒合、疤痕形成和功能障礙等併發症也至關重要。

燒傷治療

燒傷治療的重點在於穩定病情、促進創傷治療、預防感染、控制疼痛、恢復功能，同時最大限度地減少疤痕和攣縮等併發症。治療策略取決於燒傷深度、燒傷面積（TBSA）、損傷部位以及患者的整體臨床狀況。初始治療包括輸液復甦、體溫控制、鎮痛以及評估任何併發症，例如吸入性損傷。燒傷創面處理包括清潔、清創、必要時使用局部抗菌藥物、適當的敷料以及傷口覆蓋策略，以促進癒合和預防感染。對於深度或大面積燒傷，可採用更先進的治療方法，例如酵素清創、再生醫學以及手術切除並植皮。

燒傷流行病學

燒傷流行病學分析和預測的主要發現

  • 根據 DelveInsight 的分析，預計到 2025 年，七個主要國家的新增燒傷病例數約為 5,497,000 例。
  • 在歐盟四國和英國中，預計到2025年，英國新增燒傷病例數最多（約285,900例），其次是法國（約205,000例）。另一方面，預計到2025年，義大利的病例數最少，約為120,000例。
  • 依嚴重程度，燒傷分為「一度燒傷」、「二度燒傷」、「三度燒傷」或「未指明程度」。在歐盟四國和英國，二度燒傷病例最多，約76.8萬例。
  • 在美國，按原因分類，41% 的病例是由火災引起的，31% 是由熱水引起的，9% 是由接觸引起的，4% 是由電引起的，4% 是由化學物質引起的，12% 是由其他原因引起的。
  • 據估計，到 2025 年，日本將有 33 萬例燒傷病例需要醫療救治。

燒傷治療市場展望

目前燒傷治療的重點在於傷口穩定、感染預防、組織保護和皮膚功能恢復，治療方法取決於燒傷的嚴重程度、深度和燒傷面積（TBSA）。標準治療包括輸液、疼痛管理、創傷護理、局部抗生素、清創和手術介入。然而，傳統治療方法主要側重於傷口管理，在實現真正的組織再生方面存在局限性。

對於嚴重燒傷，早期切除後進行自體薄層皮膚移植（STSG）仍然是標準治療方法。然而，由於供皮區短缺、手術負擔、疤痕形成和攣縮等限制因素，仍有許多未被滿足的需求。

先進的治療方案包括NexoBrid，這是一種主要成分為鳳梨蛋白酶的生物製藥酶清創劑，用於選擇性去除燒傷痂皮；以及StrataGraft，這是一種生物工程化的同種異體細胞/組織衍生皮膚替代物，用於治療深度部分厚度燒傷。此外，RECELL（一種細胞採集和處理醫療設備，可自體生成自體皮膚細胞）和Epicel（培養的表皮自體移植片，一種細胞療法）等技術旨在改善傷口縫合效果，並減少對傳統移植手術的依賴。

燒傷治療市場正朝著再生醫學、組織工程皮膚替代物和細胞療法的方向發展。新興產品如denovoSkin（CUTISS AG公司）正在研發中，這是一種源自患者自身組織的生物工程真皮-表皮複合皮膚替代物，旨在促進皮膚再生並克服現有移植療法的局限性。 denovoSkin目前正在瑞士和歐盟進行成人和青少年嚴重燒傷的III期臨床試驗，並已獲得瑞士藥品管理局（Swissmedic）、歐洲藥品管理局（EMA）和美國食品藥物管理局（FDA）的孤兒藥資格認定。 AGLE-102（Aegle Therapeutics公司）是一種利用源自間質幹細胞的細胞外囊泡的再生醫學產品，代表了一種針對組織修復和發炎調節的新方法。

  • 酵素傷口清創劑，如anacaulase-bcdb（NexoBrid），透過蛋白水解活性酵素分解燒傷痂皮，從而選擇性地去除壞死組織，同時保留健康的傷口結構。
  • 再生皮膚替代品：StrataGraft 和 denovoSkin 等療法旨在透過提供細胞衍生或生物工程皮膚成分來恢復受損的皮膚結構，從而支持皮膚再生、組織修復和傷口縫合。

目錄

第1章：主要見解

第2章：引言

第3章執行摘要

第4章 主要事件

第5章 伯恩斯：流行病學與市場調查方法

第6章 伯恩斯：市場概覽

  • 臨床狀況分析
  • 2025年7個主要國家燒傷治療市場佔有率（依治療方法分類）
  • 2036年7個主要國家燒傷治療市場佔有率（依治療方法分類）

第7章 燒傷：疾病背景與概述

  • 病因
  • 燒傷：分類
  • 燒傷嚴重程度評估
  • 病理生理學
  • 創傷治療階段
  • 系統反應
  • 診斷、篩檢和預防
    • 診斷指南

第8章 管理和治療

  • 治療流程
  • 治療指南
    • 美國燒傷協會成人燒傷患者急性疼痛管理指南
    • 歐洲燒傷護理指南
    • 傷口和燒傷指南 - 燒傷管理指南

第9章 燒傷：流行病學和病患群體

  • 前提和基礎
  • 七個主要國家需要治療的新增燒傷病例數
  • 七大主要國家需要住院治療的燒傷患者新增病例數
  • 美國
    • 美國需要治療的新增燒傷病例數
    • 美國按性別分類的新增燒傷病例數
    • 美國新發燒傷病例數（依病因分類）。
    • 美國以嚴重程度分類的新增燒傷病例數
    • 美國新增住院燒傷患者人數
  • 歐盟4和英國
    • 歐盟四國和英國新增燒傷患者病例
    • 歐盟四國和英國按性別治療的新增燒傷病例
    • 歐盟四國和英國按病因分類的新增燒傷病例
    • 歐盟四國和英國按嚴重程度分類的新增燒傷病例數
    • 歐盟四國和英國新增燒傷住院病例
  • 日本
    • 日本新增燒傷病例數
    • 日本按性別分類的新增燒傷病例數
    • 日本接受治療的新增燒傷病例數量，依病因分類。
    • 日本以嚴重程度分類的新增燒傷病例數
    • 日本新增燒傷住院病例數

第10章 燒傷：患者病情進展

第11章 非處方藥

  • 商業治療方案的競爭格局
  • Anacaurase-bcdb（NEXOBRID）：MediWound
    • 產品概述
    • 監管里程碑
    • 其他發展活動
    • 主要臨床試驗概述
    • 分析師意見

第12章 新興療法

  • 新興療法的競爭格局
  • MW-III：Skingenix
    • 產品概述
    • 其他發展活動
    • 臨床開發
    • 安全性和有效性
    • 分析師意見
  • AGLE-102：Aegle Therapeutics

第13章 伯恩斯：七國集團分析

  • 市場展望
  • 聯合分析
  • 市場預測的關鍵假設
    • 成本假設和回扣
    • 價格趨勢
    • 對類似產品的評價
    • 發布年份及療程的普及程度
  • 伯恩斯：市場規模，主要7個國家
  • 市場規模：美國
    • 伯恩斯：美國市場規模
    • 美國燒傷：按治療方法分類的市場規模
  • 市場規模：歐盟四國及英國
    • 伯恩斯：市場規模，歐盟4國和英國
    • 燒傷：依治療方法分類的市場規模，歐盟四國和英國
  • 市場規模：日本
    • 伯恩斯：日本市場規模

第14章 燒傷：未被滿足的需求

第15章 伯恩斯：SWOT 分析

第16章 伯恩斯：關鍵意見領袖

  • 專家和意見領袖訪談亮點

第17章 伯恩斯：市場進入與報銷

  • 美國
    • 美國醫療保險和醫療補助服務中心（CMS）
  • 歐盟4和英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
  • 英國
  • 日本
  • 2025年市場進入與定價政策趨勢總結與比較
  • 伯恩斯：治療藥物的市場准入和報銷

第18章附錄

第19章 DelveInsight 服務

第20章免責聲明

第21章：關於DelveInsight

Product Code: DIMI1577

Burn Insights and Trends

  • The burn care landscape remains associated with a high clinical burden, driven by severe inflammatory, immune, and metabolic responses that can progress to shock, infection, organ failure, and long-term functional impairment, along with significant physical and psychological impact.
  • Current management is centered on a combination of resuscitation, wound care, infection control, pain management, debridement, and surgical intervention, with treatment selection guided by burn depth and total body surface area (TBSA), which remain key determinants of outcomes and resource utilization.
  • Despite advances in supportive care, limitations persist in achieving rapid wound closure, optimal scar outcomes, and full tissue regeneration, particularly in deep partial-thickness and full-thickness burns, where surgical intervention remains the mainstay of treatment.
  • The approved advanced therapy landscape includes NexoBrid (enzymatic debridement), StrataGraft (regenerative skin substitute), and other cellular approaches such as RECELL and Epicel, reflecting a gradual shift toward biologically driven and tissue-preserving strategies.
  • The emerging pipeline is increasingly focused on regenerative and tissue engineered solutions, including denovoSkin (CUTISS AG) and AGLE-102 (Aegle Therapeutics), aiming to improve skin regeneration, reduce donor-site dependence, and enhance long-term functional and cosmetic outcomes, though adoption will depend on clinical validation and regulatory success.
  • Overall, while surgical grafting remains the gold standard, the burn treatment landscape is progressively evolving toward enzymatic debridement and regenerative medicine-based approaches, driven by unmet needs in healing speed, scarring reduction, and functional restoration.

DelveInsight's 'Burn - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the Burn, historical and forecasted epidemiology, as well as the Burn market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Burn market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, Burn patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in Burn and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Burn Market

  • Increasing Global Burden of Burn Injuries

The continued prevalence of thermal injuries, industrial accidents, electrical burns, and fire-related trauma is driving demand for effective burn management therapies. Severe burns often require prolonged wound care, infection control, and reconstructive interventions, creating a sustained need for advanced treatment options.

  • High Unmet Need for Faster Healing and Improved Scar Outcomes

Delayed wound closure, hypertrophic scarring, and functional complications remain major challenges in burn recovery. This is accelerating development of therapies aimed at enhancing re-epithelialization, improving tissue regeneration, and reducing long-term scarring.

  • Rising Burn Wound Infections and Antimicrobial Resistance

Loss of skin barrier integrity after burns increases susceptibility to bacterial colonization and infection. Growing concerns around antimicrobial-resistant pathogens are driving demand for novel antimicrobial strategies and improved infection management approaches.

  • Expansion of Regenerative and Biologic Therapies

Advances in stem cell therapies, extracellular vesicles, growth factors, and bioengineered approaches are creating new opportunities to enhance angiogenesis, modulate inflammation, and improve burn wound regeneration.

Burn Understanding and Treatment Algorithm

Burn Overview and Diagnosis

Burns are traumatic injuries involving damage to the skin and underlying tissues caused by thermal, chemical, electrical, radiation, or other sources. Burn severity is classified based on depth (superficial, partial-thickness, and full-thickness) and extent of injury, including total body surface area (TBSA) involvement. Severe burns are associated with tissue necrosis, inflammation, immune dysfunction, infection risk, delayed wound healing, and scarring. Despite advances in wound care, debridement, infection management, and reconstructive procedures, significant unmet needs remain due to complications such as hypertrophic scarring, contractures, and impaired quality of life, driving development of advanced burn therapies focused on improving healing and tissue regeneration.

Diagnosis of burns is primarily based on assessment of injury depth, total body surface area (TBSA) involvement, and severity to guide treatment decisions. Evaluation includes a detailed history of the mechanism of injury, burn source, timing, and associated trauma, followed by clinical examination to assess wound characteristics, burn depth, anatomical location, and complications such as inhalation injury or infection. Additional investigations may be performed in severe cases to evaluate systemic involvement. Accurate burn assessment is essential for guiding resuscitation, debridement, wound management, infection control, and reconstructive strategies, while reducing complications such as delayed healing, scarring, and functional impairment.

Burn Treatment

Treatment of burns focuses on stabilization, wound healing, infection prevention, pain control, and functional recovery while reducing complications such as scarring and contractures. Management is based on burn depth, total body surface area (TBSA) involvement, injury location, and overall clinical status. Initial care includes fluid resuscitation, temperature control, analgesia, and assessment of associated injuries such as inhalation injury. Burn wound management involves cleaning, debridement, topical antimicrobial therapy when indicated, appropriate dressings, and wound coverage strategies to support healing and prevent infection. Advanced approaches, including enzymatic debridement, regenerative therapies, and surgical excision with skin grafting, may be used for deeper or extensive burns.

Burn Unmet Needs

The section "unmet needs of Burn" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Delayed onset of current pharmacological therapies

2. High burden of hypertrophic scarring and contracture formation

3. Increasing challenges in burn wound infection management and antimicrobial resistance

4. Need for safer and more effective alternatives to surgical debridement and grafting, and others.....

Burn Epidemiology

Key Findings from Burn Epidemiological Analysis and Forecast

  • According to DelveInsight's analysis, The total Incident cases of burn injury in the 7MM were ~ 5,497,000 cases in 2025.
  • Among EU4 and the UK, the highest Incident cases of Burn injury that require medical treatment were recorded in the UK (~285,900) followed by France (~205,000), in 2025. On the other hand, Italy accounted for the least cases, approximately 120,000 in 2025.
  • On the basis of severity, burns was bifurcated into First-degree, Second-degree, Third-degree, and Unspecified. In EU4 and the UK, Second-degree burns accounted for the maximum number of cases, which was approximately 768,000.
  • In the United States, among etiology-specific cases 41% cases were due to flame, 31% cases were of scald, 9% cases of contact, 4% cases of electrical, 4% cases of chemical and 12% cases were of other burn.
  • Japan recorded an estimated ~330,000 burn injury cases requiring medical treatment in 2025.

Burn Drug Analysis & Competitive Landscape

The Burn drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I/II-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the Burn treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the Burn therapeutics market.

Approved Therapies for Burn

Anacaulase-bcdb (NEXOBRID): MediWound

NexoBrid is MediWound's FDA-approved enzymatic debridement therapy developed for the removal of eschar in deep partial-thickness and full-thickness thermal burns. The therapy addresses a key unmet need in burn care by providing a non-surgical, selective eschar removal approach, aiming to reduce reliance on surgical debridement and support effective wound-bed preparation.

Following commercialization, NexoBrid has demonstrated increasing adoption in the U.S. burn care setting, with Vericel reporting expanding utilization across more than 70 burn centers and continued growth in product uptake. MediWound has also expanded manufacturing capacity to support anticipated global demand, reflecting increasing commercial focus on enzymatic burn management.

Burn Pipeline Analysis

DenovoSkin: CUTISS

DenovoSkin being developed by CUTISS, is bio-engineered within large quantities (>1:100) with a thick, double layer, robust structure. DenovoSkin is a patented, personalized, autologous bio-engineered human skin graft classified as Advanced Therapy Medical Product (ATMP). In parallel, CUTISS is advancing denovoSkin in an ongoing Phase III clinical trial for adolescents and adults with severe burns across the EU and Switzerland.

MW-III: Skingenix

MW-III is a topical product being evaluated for second-degree burns in adult patients. The drug is a botanical drug product developed for treating burns and other cutaneous wounds, which will be made from natural ingredients. In February 2023, the first patient was treated with Skingenix's investigational drug MW-III in a Phase II trial at MedStar Washington Hospital Center, led by Dr. Jeffrey Shupp. Currently, the drug is in Phase II study (NCT01297400) of the clinical trial.

Burn Key Players, Market Leaders and Emerging Companies

  • Vericel Corporation
  • Skingenix
  • Aegle Therapeutics
  • CUTISS, and others

Burn Drug Updates

  • In March 2026, CUTISS announced publication of 1-year Phase II results for denovoSkin in reconstructive surgery, reporting favorable safety and clinical outcomes with the bioengineered dermo-epidermal skin substitute.
  • In May 2025, CUTISS completed an interim analysis of its Phase II clinical trial evaluating the safety and efficacy of DenovoSkin in pediatric patients with severe burns. The analysis confirmed a favorable safety profile and demonstrated promising signals of efficacy, supporting the continued clinical development of denovoSkin for pediatric burn treatment.
  • In January 2024, Aegle Therapeutics announced positive 12-week data for the first patient enrolled in a Phase I/IIa clinical trial of AGLE-102 for the treatment of severe second-degree burns. The patient achieved 99% epithelialization of the burn wound and had a significant reduction in edema within seven days of treatment. Subsequent doses of AGLE-102 were not required.

Drug Class Insights

Burn Market Outlook

The current burn treatment landscape focuses on wound stabilization, infection prevention, tissue preservation, and restoration of skin function, with management determined by burn severity, depth, and TBSA involvement. Standard care includes fluid resuscitation, pain management, wound care, topical antimicrobials, debridement, and surgical intervention. However, conventional therapies largely support wound management and have limited ability to achieve true tissue regeneration.

For severe burns, early excision followed by autologous split-thickness skin grafting (STSG) remains the standard of care, but limitations such as donor-site scarcity, surgical burden, scarring, and contracture formation continue to drive unmet need.

Advanced treatment options include NexoBrid, a bromelain-based enzymatic debridement biologic medicinal product used for selective burn eschar removal, and StrataGraft, a bioengineered allogeneic cellular/tissue-based skin substitute for deep partial-thickness burns. Additional technologies such as RECELL, a cell-harvesting and processing medical device that generates autologous spray-on skin cells, Epicel (cultured epidermal autograft), a cell-based therapy aim to improve wound closure outcomes and reduce reliance on conventional grafting procedures.

The burn market is shifting toward regenerative medicine, tissue-engineered skin substitutes, and cell-based therapies. Emerging assets such as denovoSkin (CUTISS AG), an autologous bioengineered dermo-epidermal skin substitute, are being developed to support skin regeneration and address limitations of current grafting approaches. denovoSkin is advancing in Phase III clinical development for severe burns in adults and adolescents in Switzerland and the European Union and has received Orphan Drug Designation from Swissmedic, EMA, and the FDA. AGLE-102 (Aegle Therapeutics), an extracellular vesicle-based regenerative therapy derived from allogeneic mesenchymal stem cells, represents another emerging approach targeting tissue repair and inflammatory modulation.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Burn (2022-2036 Forecast)

The Burn treatment landscape comprises antidepressants, anxiolytics, adjunctive agents, and emerging novel therapies, each targeting different aspects of neurotransmitter imbalance and symptom control.

  • Enzymatic Debridement Agents: Therapies such as anacaulase-bcdb (NexoBrid) act by enzymatically degrading burn eschar through proteolytic activity, enabling selective removal of non-viable tissue while preserving viable wound structures.
  • Regenerative Skin Substitutes: Therapies such as StrataGraft and denovoSkin are designed to restore damaged skin architecture by providing cellular or bioengineered skin components that support skin regeneration, tissue repair, and wound closure.

Burn Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the Burn drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The uptake of therapies in the burn market is expected to vary across standard surgical approaches, approved advanced therapies, and emerging regenerative technologies. Autologous split thickness skin grafting (STSG) is expected to remain the standard of care due to established clinical experience, while advanced therapies such as NexoBrid and StrataGraft may see increasing adoption due to their ability to address limitations of conventional burn management through enzymatic debridement and regenerative skin replacement approaches.

Emerging therapies such as denovoSkin (CUTISS AG) and AGLE-102 (Aegle Therapeutics) are expected to gain gradual adoption as clinical data mature, driven by their potential to improve skin regeneration, reduce surgical burden, and address unmet needs such as donor-site limitations and scarring.

Detailed insights of emerging therapies' drug uptake is included in the report.

Market Access and Reimbursement of Burn

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

NOTE: Further Details are provided in the final report....

Burn Therapies Price Scenario & Trends

Pricing and analogue assessment of Burn therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Further details are provided in the final report....

Industry Experts and Physician Views for Burn

To keep up with Burn market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the Burn emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in Burn, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights at country level. Centers such as the USDA Forest Service, Pacific Southwest Research Station, Department of Plastic and Reconstructive Surgery, Germany, and Department of Trauma and Critical Care Medicine, Tokyo, Japan, etc. were contacted.Their opinion helps understand and validate current and emerging Burn therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in Burn.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of Burn, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

  • The report covers a segment of key events, an executive summary, a descriptive overview of Burn, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
  • Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
  • Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
  • A detailed review of the Burn market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Burn market.

Report Insights

  • Burn Patient Population Forecast
  • Burn Therapeutics Market Size
  • Burn Pipeline Analysis
  • Burn Market Size and Trends
  • Burn Market Opportunity (Current and forecasted)

Report Key Strengths

  • Epidemiology-based (Epi-based) Bottom-up Forecasting
  • Artificial Intelligence (AI)-Enabled Market Research Report
  • 11-Year Forecast
  • Burn Market Outlook (North America, Europe, Asia-Pacific)
  • Patient Burden Trends (By Geography)
  • Burn Treatment Addressable Market (TAM)
  • Burn Competitive Landscape
  • Burn Major Companies Insights
  • Burn Price Trends and Analogue Assessment
  • Burn Therapies Drug Adoption/Uptake
  • Burn Therapies Peak Patient Share Analysis

Report Assessment

  • Burn Current Treatment Practices
  • Burn Unmet Needs
  • Burn Clinical Development Analysis
  • Burn Emerging Drugs Product Profiles
  • Burn Market attractiveness
  • Burn Qualitative Analysis (SWOT and conjoint analysis)

FAQs:

Market Insights

  • What was the Burn market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
  • What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
  • What can be the future treatment paradigm of Burn?
  • What are the disease risks, burdens, and unmet needs of Burn? What will be the growth opportunities across the 7MM concerning the patient population with Burn?
  • Who is the major future competitor in the market, and how will the competitors affect their market share?
  • What are the current options for the treatment of Burn? What are the current guidelines for treating Burn in the US, Europe, and Japan?

Reasons to Buy:

  • The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Burn market.
  • Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
  • Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
  • Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
  • Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
  • Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
  • To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
  • Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
  • This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

  • 4.1. Key Conferences And Meetings
  • 4.2. Key Transactions And Collaborations
  • 4.3. News Flow

5. Epidemiology and Market Methodology of Burn

6. Burn Market Overview at a Glance

  • 6.1. Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
  • 6.2. Market Share of Burn By Therapies (%) in the 7MM in 2025
  • 6.3. Market Share of Burn By Therapies (%) in the 7MM in 2036

7. Disease Background And Overview of Burn

  • 7.1. Introduction
  • 7.2. Etiology
  • 7.3. Classification of Burn
  • 7.4. Evaluation of Burn Severity
  • 7.5. Pathophysiology
  • 7.6. Phases of Wound Healing
  • 7.7. Systemic Response
  • 7.8. Diagnosis, screening, and prevention
    • 7.8.1. Diagnosis Guidelines
      • 7.8.1.1. The wound/burn guidelines -Guidelines for the management of burns

8. Management and Treatment

  • 8.1. Treatment Algorithm
  • 8.2. Treatment Guidelines
    • 8.2.1. American Burn Association Guidelines on the Management of Acute Pain in the Adult Burn Patient
    • 8.2.2. European Practice Guidelines for Burn Care
    • 8.2.3. The wound/burn guidelines -Guidelines for the management of burn

9. Epidemiology and Patient Population of Burn

  • 9.1. Key Findings
  • 9.2. Assumption and Rationale
  • 9.3. Incident Cases of Burn Patients Requiring Treatment in the 7MM
  • 9.4. Incident Cases of Hospitalized Burn Patients in the 7MM
  • 9.5. The United States
    • 9.5.1. Incident Cases of Burn Patients Requiring Treatment in the US
    • 9.5.2. Treated Burn Injuries Gender-specific Incident Cases in the US
    • 9.5.3. Treated Burn Injuries Etiology-specific Incident Cases in the US
    • 9.5.4. Treated Burn Injuries Severity-specific Incident Cases in the US
    • 9.5.5. Hospitalized Burn Patients Incident Cases in the US
  • 9.6. EU4 and the UK
    • 9.6.1. Incident Cases of Burn Patients Requiring Treatment in EU4 and the UK
    • 9.6.2. Treated Burn Injuries Gender-specific Incident Cases in EU4 and the UK
    • 9.6.3. Treated Burn Injuries Etiology-specific Incident Cases in EU4 and the UK
    • 9.6.4. Treated Burn Injuries Severity-specific Incident Cases in EU4 and the UK
    • 9.6.5. Hospitalized Burn Patients Incident Cases in EU4 and the UK
  • 9.7. Japan
    • 9.7.1. Incident Cases of Burn Patients Requiring Treatment in Japan
    • 9.7.2. Treated Burn Injuries Gender-specific Incident Cases in Japan
    • 9.7.3. Treated Burn Injuries Etiology-specific Incident Cases in Japan
    • 9.7.4. Treated Burn Injuries Severity-specific Incident Cases in Japan
    • 9.7.5. Hospitalized Burn Patients Incident Cases in Japan

10. Patient Journey of Burn

11. Marketed Therapies

  • 11.1. Competitive Landscape of Marketed Therapies
  • 11.2. Anacaulase-bcdb (NEXOBRID): MediWound
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Summary of Pivotal Clinical Trials
    • 11.2.5. Analyst Views

12. Emerging Therapies

  • 12.1. Competitive Landscape of Emerging Therapies
  • 12.2. MW-III: Skingenix
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
      • 12.2.3.1. Clinical Trial Information
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Analyst's View
  • 12.3. AGLE-102: Aegle Therapeutics
    • 12.3.1. Product Description
    • 12.3.2. Other Developmental Activities
    • 12.3.3. Clinical Development
      • 12.3.3.1. Clinical Trial Information
    • 12.3.4. Safety and Efficacy
    • 12.3.5. Analyst's View

Continued emerging therapies will be provided in the final report.

13. Burn: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Market Outlook
  • 13.3. Conjoint Analysis
  • 13.4. Key Market Forecast Assumptions
    • 13.4.1. Cost Assumptions and Rebates
    • 13.4.2. Pricing Trends
    • 13.4.3. Analogue Assessment
    • 13.4.4. Launch Year and Therapy Uptakes
  • 13.5. Total Market Size of Burn in the 7MM
  • 13.6. United States Market Size
    • 13.6.1. Total Market Size of Burn in the United States
    • 13.6.2. Market Size of Burn by Therapies in United States
  • 13.7. EU4 and the UK Market Size
    • 13.7.1. Total Market Size of Burn in EU4 and the UK
    • 13.7.2. Market Size of Burn by Therapies in EU4 and the UK
  • 13.8. Japan Market Size
    • 13.8.1. Total Market Size of Burn in Japan
    • 13.8.2. Market Size of Burn by Therapies in Japan

14. Unmet Needs of Burn

15. SWOT Analysis of Burn

16. KOL Views of Burn

  • 16.1. Expert/KOL Interview Highlights

17. Market Access and Reimbursement of Burn

  • 17.1. United States
    • 17.1.1. Centre for Medicare and Medicaid Services (CMS)
  • 17.2. EU4 and the UK
    • 17.2.1. Germany
    • 17.2.2. France
    • 17.2.3. Italy
    • 17.2.4. Spain
  • 17.5. United Kingdom
  • 17.3. Japan
  • 17.4. Summary and comparison of Market Access and Pricing Policy Developments in 2025
  • 17.5. Market Access and Reimbursement of Burn Therapies

18. Appendix

  • 18.1. Bibliography
  • 18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Tables

  • Table 1 Summary of Burn Market and Epidemiology (2022-2036)
  • Table 2 Key Events for Burn
  • Table 3 The Haddon Matrix for Burn Prevention
  • Table 4 Recommendations
  • Table 5 Incident Cases of Burn Patients Requiring Treatment in the 7MM (2022-2036)
  • Table 6 Incident Cases of Hospitalized Burn Patients in the 7MM (2022-2036)
  • Table 7 Incident Cases of Burn Patients Requiring Treatment in the US (2022-2036)
  • Table 8 Gender-specific Incident Cases of Treated Burn Injuries in the US (2022-2036)
  • Table 9 Etiology-specific Incident Cases of Cases of Treated Burn Injuries in the US (2022-2036)
  • Table 10 Severity-specific Incident Cases of Treated Burn Injuries in the US (2022-2036)
  • Table 11 Incident Cases of Hospitalized Burn Patients in the US (2022-2036)
  • Table 12 Incident Cases of Burn Patients Requiring Treatment in the EU4 and the UK (2022-2036)
  • Table 13 Gender-specific Incident Cases of Treated Burn Injuries in the EU4 and the UK (2022-2036)
  • Table 14 Etiology-specific Incident Cases of Treated Burn Injuries in EU4 and the UK (2022-2036)
  • Table 15 Severity-specific Incident Cases of Treated Burn Injuries in the EU4 and the UK (2022-2036)
  • Table 16 Incident Cases of Burn Patients Requiring Treatment in Japan (2022-2036)
  • Table 17 Gender-specific Incident Cases of Treated Burn Injuries in Japan (2022-2036)
  • Table 18 Etiology-specific Incident Cases of Cases of Treated Burn Injuries in Japan (2022-2036)
  • Table 19 Severity-specific Incident Cases of Treated Burn Injuries in Japan (2022-2036)
  • Table 20 Incident Cases of Hospitalized Burn Patients in Japan (2022-2036)
  • Table 21 Key Cross Of Marketed Drugs
  • Table 22 NexoBrid, Clinical Trial Description, 2024
  • Table 23 Kerecis Omega3 Burn, Clinical Trial Description, 2024
  • Table 24 StrataGraft, Clinical Trial Description, 2024
  • Table 25 RECELL Autologous Cell Harvesting Device, Clinical Trial Description, 2024
  • Table 26 KeraStat Gel, Clinical Trial Description, 2024
  • Table 27 NovoSorb Biodegradable Temporising Matrix (BTM), Clinical Trial Description, 2024
  • Table 28 Oleogel-S10 ointment, Clinical Trial Description, 2024
  • Table 29 Comparison of Emerging Drugs for Treatment
  • Table 30 EHSG-KF (synonym denovoSkin), Clinical Trial Description, 2024
  • Table 31 MW-III, Clinical Trial Description, 2024
  • Table 32 CellMist System, Clinical Trial Description, 2024
  • Table 33 Key Market Forecast Assumptions for EHSG-KF (denovoSkin)
  • Table 34 Key Market Forecast Assumptions for MW-III
  • Table 35 Key Market Forecast Assumptions for CellMist System
  • Table 36 Total Market Size of Burns in the 7MM, in USD million (2022-2036)
  • Table 37 Total Market Size of Burns by Therapies in the 7MM, in USD million (2022-2036)
  • Table 38 Total Market Size of Burns in the US, in USD million (2022-2036)
  • Table 39 The Market Size of Burns by Therapies in the US, in USD million (2022-2036)
  • Table 40 Total Market Size of Burns in EU4 and the UK, in USD million (2022-2036)
  • Table 41 The Market Size of Burns by Therapies in EU4 and the UK, in USD million (2022-2036)
  • Table 42 Total Market Size of Burns in Japan, in USD million (2022-2036)
  • Table 43 The Market Size of Burns by Therapies in Japan, in USD million (2022-2036)

List of Figures

  • Figure 1 The Five Mechanisms That Can Cause a Burn
  • Figure 2 Burn Depth
  • Figure 3 Wallace Rule of Nines
  • Figure 4 Lund and Browder Chart
  • Figure 5 Jackson's Burns Zones
  • Figure 6 Systemic Changes That Occur After a Burn Injury
  • Figure 7 Therapeutic Stepladder Algorithm in Burns
  • Figure 8 Four Phases of Wound Healing
  • Figure 9 The Phases of Burn Care
  • Figure 10 Diagnostic And Therapeutic Algorithms for Burn Injury
  • Figure 11 Burns Patient Journey
  • Figure 12 Incident Cases of Burn Patients Requiring Treatment in the 7MM (2022-2036)
  • Figure 13 Incident Cases of Hospitalized Burn Patients in the 7MM (2022-2036)
  • Figure 14 Incident Cases of Burn Patients Requiring Treatment in the US (2022-2036)
  • Figure 15 Gender-specific Incident Cases of Treated Burn Injuries in the US (2022-2036)
  • Figure 16 Etiology-specific Incident Cases of Treated Burn Injuries in the US (2022-2036)
  • Figure 17 Severity-specific Incident Cases of Treated Burn Injuries in the US (2022-2036)
  • Figure 18 Incident Cases of Hospitalized Burn Patients in the US (2022-2036)
  • Figure 19 Incident Cases of Burn Patients Requiring Treatment in EU4 and the UK (2022-2036)
  • Figure 20 Gender-specific Incident Cases of Treated Burn Injuries in EU4 and the UK (2022-2036)
  • Figure 21 Etiology-specific Incident Cases of Treated Burn Injuries in EU4 and the UK (2022-2036)
  • Figure 22 Severity-specific Incident cases of Treated Burn Injuries in EU4 and the UK (2022-2036)
  • Figure 23 Incident Cases of Hospitalized Burn Patients in EU4 and the UK (2022-2036)
  • Figure 24 Incident Cases of Burn Patients Requiring Treatment in Japan (2022-2036)
  • Figure 25 Gender-specific Incident Cases of Treated Burn Injuries in Japan (2022-2036)
  • Figure 26 Etiology-specific Incident Cases of Treated Burn Injuries in Japan (2022-2036)
  • Figure 27 Severity-specific Incident Cases of Treated Burn Injuries in Japan (2022-2036)
  • Figure 28 Incident Cases of Hospitalized Burn Patients in Japan (2022-2036)
  • Figure 29 Total Market Size of Burns in the 7MM, in USD million (2022-2036)
  • Figure 30 Total Market Size of Burns by Therapies in the 7MM, in USD million (2022-2036)
  • Figure 31 Total Market Size of Burns in the US, in USD million (2022-2036)
  • Figure 32 The Market Size of Burns by Therapies in the US, in USD million (2022-2036)
  • Figure 33 Total Market Size of Burns in EU4 and the UK, in USD million (2022-2036)
  • Figure 34 The Market Size of Burns by Therapies in EU4 and the UK, in USD million (2022-2036)
  • Figure 35 Total Market Size of Burns in Japan, in USD million (2022-2036)
  • Figure 36 The Market Size of Burns by Therapies in Japan, in USD million (2022-2036)
  • Figure 37 SWOT Analysis of Burns
  • Figure 38 Unmet Needs of Burns
  • Figure 39 Health Technology Assessment
  • Figure 40 Reimbursement Process in Germany
  • Figure 41 Reimbursement Process in France
  • Figure 42 Reimbursement Process in Italy
  • Figure 43 Reimbursement Process in Spain
  • Figure 44 Reimbursement Process in the United Kingdom
  • Figure 45 Reimbursement Process in Japan